American Society of Hirudotherapy

Cutaneous Pseudolymphoma Due to Hirudotherapy

Research article published in Turkiye parazitolojii dergisi (2019)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Case reportClinical TrialsTemiz S et al. · Turkiye parazitolojii dergisi, 2019

Abstract

Pseudolymphoma, also known as Jessner’s lymphocytic infiltration, is a benign but usually chronic, T-cell infiltrating disease with erythematous papules and plaques usually seen on the skin of the face, neck, and back. The use of leech therapy also known as hirudotherapy has increased in recent years. Here, we report a 52-year-old male patient who had undergone hirudotherapy in his neck and developed infiltrating plaques after four months. A skin biopsy confirmed the diagnosis of Jessner’s lymphocytic infiltration. In parallel with the increasing use of hirudotherapy in recent years, the side-effect reports will likely to increase. Indications and contraindications of hirudotherapy, which is being used officially in hospitals, should be taken into consideration.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeCase ReportsJournal Article
Indexed MeSH termsDiagnosis, DifferentialHumansLeechingMaleMiddle AgedNeckPseudolymphomaSkin Diseases

Summary

Pseudolymphoma, also known as Jessner’s lymphocytic infiltration, is a benign but usually chronic, T-cell infiltrating disease with erythematous papules and plaques usually seen on the skin of the face, neck, and back.

Why This Matters for Hirudotherapy

This case report documents a 52-year-old male who developed cutaneous pseudolymphoma (Jessner's lymphocytic infiltration) at the neck site four months after receiving hirudotherapy, confirmed by skin biopsy. The report is directly relevant to hirudotherapy practice as it describes a cutaneous adverse event temporally and anatomically linked to leech application, contributing to the limited but growing literature on side effects associated with this increasingly utilized therapy. The authors note that as hirudotherapy use expands in clinical settings, reports of such reactions may rise, underscoring the importance of established indications and contraindications. The principal limitation is that this is a single case report with no controlled data; it does not establish incidence, mechanism, or causality beyond temporal association, and it provides no insight into the leech salivary secretome or comparative safety across hirudotherapy protocols.

Citation

Cutaneous Pseudolymphoma Due to Hirudotherapy.

Temiz S et al. · Turkiye parazitolojii dergisi, 2019

Added to ASH library: March 18, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.